Publication:
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction

Simple item page
dc.contributor.authorCascales Campos, Pedro Antonio
dc.contributor.authorGil Martínez, José
dc.contributor.authorFeliciangeli, Eduardo
dc.contributor.authorGil Gómez, Elena
dc.contributor.authorGonzález Gil, Alida
dc.contributor.authorLópez López, Víctor
dc.contributor.authorRuiz Pardo, José
dc.contributor.authorNieto Díaz, Aníbal
dc.contributor.authorParrilla Paricio, Juan José
dc.contributor.authorParrilla Paricio, Pascual
dc.contributor.departmentCirugía, Pediatría y Obstetricia y Ginecología
dc.date.accessioned2024-01-29T13:08:38Z
dc.date.available2024-01-29T13:08:38Z
dc.date.issued2015-03
dc.description© 2015. The authors. This document is the accepted version of a published work that appeared in final form in Annals of Surgical Oncology. To access the final edited and published work see https://doi.org/10.1245/s10434-014-4049-zes
dc.description.abstractEn este trabajo, se compararon 2 grupos homogéneos de pacientes con carcinomatosis peritoneal de origen ovárico recurrente, sensibles al platino en las que se realizó una citorreducción completa de la enfermedad: un grupo estaba formado por pacientes intervenidas antes y el otro después de inicio del programa de cirugía oncológica peritoneal. Bajo esta premisa se estudió como HIPEC había mejorado los resultados en pacientes con recurrencias platino-sensibles. Se trata de un aporte multidisciplinar en el que trabajamos conjuntamente los servicios de Cirugía, Ginecología y Oncología Médica. En los resultados, se encontró una mejoría a favor del tratamiento HIPEC en grupos comparables, sin diferencias significativas en ninguna de las variables preoperatorias estudiadas: Tras un análisis multivariante de los factores identificados en el análisis univariante, solo la presencia de tumores con histología indiferenciada (hazard ratio 2,57; IC 95 % 1,21–5,46; p < 0,05) fue un factor independiente asociado a una supervivencia libre de enfermedad reducida. La supervivencia libre de enfermedad a 1 y 3 años fue del 77 y 23 % en los pacientes del grupo I y del 77 y 45% diferencias clínicamente relevantes entre los 2 grupos, con una mejora evidente de la supervivencia a favor del grupo tratado con HIPEC. No se encontraron diferencias en cuanto a las complicaciones postoperatorias entre ambos grupos por lo que en este estudio se reforzó la idea de que HIPEC no incrementaba la morbilidad postoperatoria con su administración.es
dc.description.abstractBackground. We analyzed the role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) on the microscopic component of the disease in patients with a first recurrence of platinum-sensitive ovarian cancer after complete cytoreduction (CCR). Patients and Methods. We analyzed the data of 54 patients who were operated on between January 2001 and July 2012 with the diagnosis of platinum-sensitive recurrent ovarian cancer. In all patients, it was possible to achieve a CCR. Patients were divided into two groups: group I (cytoreduction alone) consisted of 22 surgical patients and group II (cytoreduction and HIPEC) consisted of 32 patients. Results. There were no significant differences in any of the preoperative variables studied. After a multivariate analysis of factors identified in the univariate analysis, only the presence of tumors with undifferentiated histology (hazard ratio 2.57; 95 % CI 1.21–5.46; p\0.05) was an independent factor associated with a reduced disease-free survival. The 1- and 3-year disease-free survival was 77 and 23 % in patients from group I and 77 and 45 % in patients from group II, respectively, with a tendency, but no significant differences (p = 0.078). There was no significant difference in postoperative morbidity between the two groups. Conclusions. The administration of HIPEC in patients in whom it is possible to achieve a CCR of the disease has not increased postoperative morbidity and mortality rates in our center. HIPEC with paclitaxel is effective in the treatment of microscopic disease in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction, although with no statistically significant difference.es
dc.formatapplication/pdfes
dc.format.extent9es
dc.identifier.citationAnnals of Surgical Oncology 2015 Mar 22(3):987-993
dc.identifier.doihttps://doi.org/10.1245/s10434-014-4049-z
dc.identifier.issn1068-9265
dc.identifier.urihttp://hdl.handle.net/10201/137976
dc.languageenges
dc.publisherspringeres
dc.relationSin financiación externa a la Universidades
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectOvarian Canceres
dc.subjectPaclitaxeles
dc.subjectCytoreductive Surgeryes
dc.subjectPeritoneal Cancer Indexes
dc.subjectRecurrent Ovarian Canceres
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::617 - Cirugía. Ortopedia. Oftalmologíaes
dc.titleThe role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreductiones
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ASO RECURRENTES 2015.pdf
Size:
564.94 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos